AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17276853 — intervention group
Group type: COMPARATOR
Intervention: Conventional acid-etch conditioner with Fuji Ortho LC resin-modified glass ionomer cement
Number of subjects: 120
Study 17276853 — intervention group
Group type: COMPARATOR
Intervention: 10% polyacrylic acid with Transbond XT composite resin adhesive
Number of subjects: 120
Study 17276853 — intervention group
Group type: COMPARATOR
Intervention: 10% polyacrylic acid with Fuji Ortho LC resin-modified glass ionomer cement
Number of subjects: 120
Study 15507062 — intervention group
Group type: EXPERIMENTAL
Intervention: Relocated nursing home residents
Number of subjects: 77
Study 15507062 — intervention group
Group type: COMPARATOR
Intervention: Control group residents (not yet moved)
Number of subjects: 77
Study 11445475 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior vaginal wall suspension for urethral hypermobility (UH group)
Number of subjects: 88
Study 11445475 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair of grade 3 cystocele (C group)
Number of subjects: 88
Study 11445475 — intervention group
Group type: COMPARATOR
Intervention: Control group (continent patients)
Number of subjects: 88
Study 9722036 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME 1 mg x kg(‐1) x h(‐1) for 12 hours
Number of subjects: 11
Study 9722036 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 11
Study 8064606 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcon MZ20BD oval-optic PMMA IOL
Number of subjects: 182
Study 8064606 — intervention group
Group type: COMPARATOR
Intervention: STAAR AQ1016 round-optic silicone IOL
Number of subjects: 182
Study 3051839 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TS) adhesive, delivering 140 micrograms initially and 5 micrograms/h thereafter
Number of subjects: 96
Study 3051839 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (DHBP) 0.5 ml (1.25 mg) i.v.
Number of subjects: 96
Study 3051839 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 ml i.v.)
Number of subjects: 96
Study 3051839 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TS)
Number of subjects: 96
Study 3051839 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (DHBP)
Number of subjects: 96
Study 31206301 — intervention group
Group type: COMPARATOR
Intervention: Thyroid Doppler ultrasonography (Thyroid volume, Resistance index (RI), and Pulsatility index (PI))
Number of subjects: 60
Study 31206301 — intervention group
Group type: COMPARATOR
Intervention: Thyroid function tests
Number of subjects: 60
Study 31206301 — intervention group
Group type: COMPARATOR
Intervention: Correlation analysis
Number of subjects: 60
Study 31206301 — intervention group
Group type: COMPARATOR
Intervention: Serum ferritin levels
Number of subjects: 60
Study 28634136 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxie
Number of subjects: 1044
Study 28634136 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium (50 mg tablets, 3 times daily for 4 weeks)
Number of subjects: 1044
Study 28634136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1044
Study 25773472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers who concurrently use hookah (n = 270)
Number of subjects: 1217
Study 25773472 — intervention group
Group type: COMPARATOR
Intervention: Non-hookah users (control group)
Number of subjects: 1217
Study 23144445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cindunistat 50 mg/day
Number of subjects: 1457
Study 23144445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cindunistat 200 mg/day
Number of subjects: 1457
Study 23144445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1457
Study 23144445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cindunistat (50 or 200 mg/day)
Number of subjects: 1457
Study 21613554 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet modification (n = 118)
Number of subjects: 439
Study 21613554 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (n = 117)
Number of subjects: 439
Study 21613554 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + exercise (n = 117)
Number of subjects: 439
Study 21613554 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 87)
Number of subjects: 439
Study 21613554 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss categories (<5%, 5-9.9%, 10-14.9%, ≥15%)
Number of subjects: 439
Study 19951602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nitroprusside (group A)
Number of subjects: 92
Study 16945898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ATCC 55730 via straw (200 ml of water through a prepared straw once daily for 3 weeks)
Number of subjects: 120
Study 16945898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ATCC 55730 via tablet (one tablet once daily for 3 weeks)
Number of subjects: 120
Study 16945898 — intervention group
Group type: COMPARATOR
Intervention: Placebo straw (200 ml of water through a placebo straw once daily for 3 weeks)
Number of subjects: 120
Study 16945898 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet (one placebo tablet once daily for 3 weeks)
Number of subjects: 120
Study 14705152 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine plus nutritional supplements
Number of subjects: 26
Study 14705152 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine plus nutritional placebo
Number of subjects: 26
Study 11318062 — intervention group
Group type: EXPERIMENTAL
Intervention: Beat-based timing
Number of subjects: 0
Study 11318062 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval-based timing
Number of subjects: 0
Study 9129014 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (0.3 to 5.0 microg/kg) with filgrastim (5 microg/kg)
Number of subjects: 41
Study 9129014 — intervention group
Group type: COMPARATOR
Intervention: Placebo with filgrastim (5 microg/kg)
Number of subjects: 41
Study 8204245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 1 mg
Number of subjects: 26
Study 8204245 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 5 mg
Number of subjects: 26
Study 3294914 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine mouthrinse (20 ml for 30 s, twice daily)
Number of subjects: 96
Study 3294914 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (0.2% or 0.1% solution, 10 ml for 60 s, twice daily)
Number of subjects: 96
Study 3294914 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 ml mouthrinse for 30 s, twice daily)
Number of subjects: 96
Study 30517725 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 3362
Study 30517725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3362
Study 30517725 — intervention group
Group type: EXPERIMENTAL
Intervention: Total MUFAs and total PUFAs
Number of subjects: 3362
Study 30517725 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 PUFAs (ω-6 PUFAs)
Number of subjects: 3362
Study 26869374 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 36
Study 26869374 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial plexus blockade
Number of subjects: 36
Study 25476072 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach-based treatment
Number of subjects: 46
Study 25476072 — intervention group
Group type: COMPARATOR
Intervention: Institution-based services
Number of subjects: 46
Study 22673369 — intervention group
Group type: EXPERIMENTAL
Intervention: Human multipotent cardiovascular progenitor cells generated from human iPS cells, followed by selective differentiation into cardiomyocytes (CMs), endothelial cells (ECs), and smooth muscle cells (SMCs).
Number of subjects: 0
Study 22673369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiomyocytes purified from iPS cells derived from a patient with LEOPARD syndrome.
Number of subjects: 0
Study 20207664 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effects related to smoking cessation
Number of subjects: 3927
Study 20207664 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effects related to diet
Number of subjects: 3927
Study 20207664 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effects related to sun exposure
Number of subjects: 3927
Study 17557319 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month primary care, phone and Internet-based behavioral intervention
Number of subjects: 401
Study 17557319 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 401
Study 16045061 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (10,000 lux, n = 10)
Number of subjects: 32
Study 16045061 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density negative air ions (4.5 x 10(14) ions/s flow rate, n = 12)
Number of subjects: 32
Study 16045061 — intervention group
Group type: COMPARATOR
Intervention: Low-density negative air ions (1.7 x 10(11) ions/s, n = 10, placebo control)
Number of subjects: 32
Study 11828279 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depletion group
Number of subjects: 24
Study 11828279 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 10426235 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 600 microg
Number of subjects: 0
Study 10426235 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 microg
Number of subjects: 0
Study 10426235 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin 10 IU
Number of subjects: 0
Study 7844605 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy before diagnosis
Number of subjects: 2119
Study 7844605 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy during the 5-year period preceding breast cancer diagnosis
Number of subjects: 2119
Study 7844605 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy after breast cancer diagnosis
Number of subjects: 2119
Study 2149051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 86
Study 2149051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime + Teicoplanin
Number of subjects: 86
Study 2149051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 86
Study 2149051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin + Teicoplanin
Number of subjects: 86
Study 2149051 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (monotherapy)
Number of subjects: 86
Study 2149051 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime and Ciprofloxacin (comparison)
Number of subjects: 86
Study 85053 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 7
Study 85053 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg)
Number of subjects: 7
Study 85053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31761287 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonintubated anesthesia
Number of subjects: 0
Study 31761287 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30991136 — intervention group
Group type: EXPERIMENTAL
Intervention: S. striata mouthwash
Number of subjects: 50
Study 30991136 — intervention group
Group type: COMPARATOR
Intervention: Irsha mouthwash
Number of subjects: 50
Study 28534225 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled dietary acrylamide intake via coffee (0.15-0.17 µg/kg bw) and a meal (14.1-15.9 µg/kg bw) on days 6 and 10 respectively.
Number of subjects: 12
Study 28534225 — intervention group
Group type: COMPARATOR
Intervention: Controlled dietary acrylamide minimized diet (0.05-0.06 µg/kg bw) throughout the 13-day study period.
Number of subjects: 12
Study 28534225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of 13C3D3-AA (1 µg/kg bw) on day 6.
Number of subjects: 12
Study 26824990 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 60
Study 26824990 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study 25400681 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 IU once daily
Number of subjects: 76
Study 25400681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 22289783 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school physical activity program (12 weeks, 24 sessions of aerobic exercise)
Number of subjects: 470
Study 22289783 — intervention group
Group type: COMPARATOR
Intervention: Control group (60 children without mothers)
Number of subjects: 470
Study 20422150 — intervention group
Group type: EXPERIMENTAL
Intervention: Small dead space heat and moisture exchanger (HME)
Number of subjects: 50
Study 20422150 — intervention group
Group type: COMPARATOR
Intervention: Heated humidifier (HH)
Number of subjects: 50
Study 17940860 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride, 0.4 mg/kg
Number of subjects: 56
Study 17940860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 17940860 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride
Number of subjects: 56
Study 15878004 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control (Cardioversion)
Number of subjects: 0
Study 15878004 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control (Atrioventricular junctional ablation)
Number of subjects: 0
Study 12437389 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter and telephone recall for PCV7 vaccination (intervention group)
Number of subjects: 1234
Study 12437389 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 1234
Study 10613225 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO), 6000 U i.v. twice weekly for 3 weeks
Number of subjects: 37
Study 10613225 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 37
Study 7484202 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 21
Study 7484202 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 21
Study 1366265 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 39
Study 1366265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 39
Study 3888836 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 12
Study 3888836 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg b.i.d.)
Number of subjects: 12
Study 3888836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30113664 — intervention group
Group type: EXPERIMENTAL
Intervention: Collar use
Number of subjects: 35
Study 30113664 — intervention group
Group type: COMPARATOR
Intervention: No collar use
Number of subjects: 35
Study 29153938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine (200 mg for children, 400 mg for adolescents and adults)
Number of subjects: 607
Study 29153938 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel (50 mg/kg bodyweight and 25 mg/kg bodyweight, 6 h apart)
Number of subjects: 607
Study 29153938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine
Number of subjects: 607
Study 29153938 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 607
Study 26768923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) 65% in oxygen (O2) via mask, flow of 10 L/min
Number of subjects: 15
Study 26768923 — intervention group
Group type: COMPARATOR
Intervention: Oxygen (O2) only, flow of 10 L/min (control group)
Number of subjects: 15
Study 24566240 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult day service (ADS) use
Number of subjects: 151
Study 24566240 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention days
Number of subjects: 151
Study 24246407 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2181308 plus docetaxel/prednisone
Number of subjects: 154
Study 24246407 — intervention group
Group type: COMPARATOR
Intervention: Standard first-line docetaxel/prednisone (control arm)
Number of subjects: 154
Study 22124042 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + bone graft (HA + β TCP)
Number of subjects: 10
Study 22124042 — intervention group
Group type: COMPARATOR
Intervention: saline + bone graft (HA + β TCP)
Number of subjects: 10
Study 19127416 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B lay health worker intervention
Number of subjects: 460
Study 19127416 — intervention group
Group type: COMPARATOR
Intervention: Direct mailing of physical activity educational materials (Control)
Number of subjects: 460
Study 17431082 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic (21% Fi(O2))
Number of subjects: 13
Study 17431082 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoxic (12% Fi(O2))
Number of subjects: 13
Study 17431082 — intervention group
Group type: COMPARATOR
Intervention: Both Norm and Hypox
Number of subjects: 13
Study 15389231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day) plus atorvastatin (10 mg/day, titrated to 40 mg/day if needed)
Number of subjects: 621
Study 15389231 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day, titrated to 80 mg/day if needed)
Number of subjects: 621
Study 15389231 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 621
Study 11354527 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO beverage (5% w/v)
Number of subjects: 9
Study 11354527 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) beverage
Number of subjects: 9
Study 9519951 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate regional node dissection
Number of subjects: 240
Study 9519951 — intervention group
Group type: COMPARATOR
Intervention: Delayed regional node dissection
Number of subjects: 240
Study 9519951 — intervention group
Group type: COMPARATOR
Intervention: Delayed regional node dissection in patients with occult regional node metastases
Number of subjects: 240
Study 9519951 — intervention group
Group type: COMPARATOR
Intervention: Delayed regional node dissection in patients with regional node metastases
Number of subjects: 240
Study 9519951 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine use of immediate node dissection
Number of subjects: 240
Study 9519951 — intervention group
Group type: EXPERIMENTAL
Intervention: Status of regional nodes
Number of subjects: 240
Study 7722120 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatrilat 200 mg
Number of subjects: 12
Study 2024791 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol (15 mg by nebulizer)
Number of subjects: 40
Study 2024791 — intervention group
Group type: COMPARATOR
Intervention: Atropine (1.5 mg by nebulizer)
Number of subjects: 40
Study 7263931 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (Temgesic)
Number of subjects: 98
Study 7263931 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 98
Study 31098430 — intervention group
Group type: EXPERIMENTAL
Intervention: Friction underwear
Number of subjects: 56
Study 31098430 — intervention group
Group type: COMPARATOR
Intervention: Non-friction underwear
Number of subjects: 56
Study 28138341 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 220
Study 28138341 — intervention group
Group type: COMPARATOR
Intervention: Progressive resisted hip exercises
Number of subjects: 220
Study 25664602 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg twice a day
Number of subjects: 44
Study 25664602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 25664602 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 23388208 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain foods during the 16-week intervention
Number of subjects: 0
Study 23388208 — intervention group
Group type: COMPARATOR
Intervention: Control group (no whole-grain foods during the intervention)
Number of subjects: 0
Study 21776571 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation
Number of subjects: 32
Study 21776571 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 32
Study 21776571 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 19462694 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measured with the Kansas City Cardiomyopathy Quality of Life questionnaire (KCCQ)
Number of subjects: 0
Study 19462694 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression measured with the Geriatric Depression Scale (GDS)
Number of subjects: 0
Study 19462694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function measured with the Mini Mental State Examination (MMSE)
Number of subjects: 0
Study 19462694 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' independent evaluation of QDF variables
Number of subjects: 0
Study 17571092 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary denture service (complete dentures fitted immediately)
Number of subjects: 133
Study 17571092 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment deferred to normal waiting list, received three home visits)
Number of subjects: 133
Study 15519028 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg, equivalent to 2 cups of coffee)
Number of subjects: 184
Study 15519028 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (one cigarette)
Number of subjects: 184
Study 15519028 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking followed by caffeine intake
Number of subjects: 184
Study 15519028 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic coffee consumption and smoking
Number of subjects: 184
Study 11763244 — intervention group
Group type: EXPERIMENTAL
Intervention: OQLQ
Number of subjects: 338
Study 11763244 — intervention group
Group type: EXPERIMENTAL
Intervention: QUALEFFO
Number of subjects: 338
Study 11763244 — intervention group
Group type: COMPARATOR
Intervention: SF-36 and EQ-5D
Number of subjects: 338
Study 9507253 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser trephination
Number of subjects: 100
Study 9507253 — intervention group
Group type: COMPARATOR
Intervention: Mechanical trephination
Number of subjects: 100
Study 9507253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100